You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, January 2016
|
| DOI | 10.1186/s40425-016-0107-3 |
| Pubmed ID | |
| Authors |
Jianda Yuan, Priti S. Hegde, Raphael Clynes, Periklis G. Foukas, Alexandre Harari, Thomas O. Kleen, Pia Kvistborg, Cristina Maccalli, Holden T. Maecker, David B. Page, Harlan Robins, Wenru Song, Edward C. Stack, Ena Wang, Theresa L. Whiteside, Yingdong Zhao, Heinz Zwierzina, Lisa H. Butterfield, Bernard A. Fox |
| Abstract |
The culmination of over a century's work to understand the role of the immune system in tumor control has led to the recent advances in cancer immunotherapies that have resulted in durable clinical responses in patients with a variety of malignancies. Cancer immunotherapies are rapidly changing traditional treatment paradigms and expanding the therapeutic landscape for cancer patients. However, despite the current success of these therapies, not all patients respond to immunotherapy and even those that do often experience toxicities. Thus, there is a growing need to identify predictive and prognostic biomarkers that enhance our understanding of the mechanisms underlying the complex interactions between the immune system and cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) reconvened an Immune Biomarkers Task Force to review state of the art technologies, identify current hurdlers, and make recommendations for the field. As a product of this task force, Working Group 2 (WG2), consisting of international experts from academia and industry, assembled to identify and discuss promising technologies for biomarker discovery and validation. Thus, this WG2 consensus paper will focus on the current status of emerging biomarkers for immune checkpoint blockade therapy and discuss novel technologies as well as high dimensional data analysis platforms that will be pivotal for future biomarker research. In addition, this paper will include a brief overview of the current challenges with recommendations for future biomarker discovery. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 67% |
| Comoros | 1 | 8% |
| Unknown | 3 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 75% |
| Science communicators (journalists, bloggers, editors) | 2 | 17% |
| Practitioners (doctors, other healthcare professionals) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 523 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | <1% |
| France | 3 | <1% |
| Germany | 1 | <1% |
| Belgium | 1 | <1% |
| Iran, Islamic Republic of | 1 | <1% |
| Russia | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| Unknown | 510 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 139 | 27% |
| Student > Ph. D. Student | 83 | 16% |
| Other | 56 | 11% |
| Student > Master | 43 | 8% |
| Student > Bachelor | 43 | 8% |
| Other | 75 | 14% |
| Unknown | 84 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 101 | 19% |
| Biochemistry, Genetics and Molecular Biology | 98 | 19% |
| Agricultural and Biological Sciences | 89 | 17% |
| Immunology and Microbiology | 42 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 32 | 6% |
| Other | 62 | 12% |
| Unknown | 99 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2023.
All research outputs
#1,589,853
of 25,394,764 outputs
Outputs from Journal for Immunotherapy of Cancer
#401
of 3,428 outputs
Outputs of similar age
#27,530
of 403,147 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#2
of 16 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,428 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 403,147 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.